Gleron
Generic Name
Etoricoxib
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| gleron 90 mg tablet | ৳ 75.00 | ৳ 750.00 |
Description
Overview of the medicine
Gleron 90 mg tablet contains Etoricoxib, a selective COX-2 inhibitor, used for the relief of pain and inflammation in conditions like osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis.
Uses & Indications
Dosage
Adults
Osteoarthritis: 30 mg or 60 mg once daily. Rheumatoid Arthritis, Ankylosing Spondylitis: 60 mg or 90 mg once daily. Acute Gouty Arthritis: 120 mg once daily (for a maximum of 8 days). Acute Pain/Primary Dysmenorrhea: 120 mg once daily (for a maximum of 8 days). Chronic Musculoskeletal Pain: 60 mg once daily.
Elderly
No dose adjustment is generally required, but caution should be exercised. Start with the lowest effective dose.
Renal_impairment
No dose adjustment is needed for mild to moderate renal impairment. Use with caution in severe renal impairment; not recommended in patients with creatinine clearance <30 mL/min.
How to Take
Take Gleron 90 mg tablet orally, with or without food. Swallow the tablet whole with water. Do not crush or chew.
Mechanism of Action
Etoricoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which is responsible for the synthesis of prostaglandins, mediators of pain and inflammation. By inhibiting COX-2, it reduces prostaglandin production, leading to anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetics
Onset
Analgesic effects typically begin within 1 hour.
Excretion
Approximately 70% of the dose is excreted in the urine and 20% in the feces as metabolites.
Half life
The elimination half-life is approximately 22 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations occurring after approximately 1 hour. Oral bioavailability is about 100%.
Metabolism
Extensively metabolized in the liver, primarily via cytochrome P450 (CYP) enzymes, particularly CYP3A4, to inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to Etoricoxib or any component of the tablet
- Active peptic ulceration or gastrointestinal bleeding
- Severe hepatic dysfunction
- Severe renal dysfunction (creatinine clearance <30 mL/min)
- Congestive heart failure (NYHA Class II-IV)
- Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
- Uncontrolled hypertension
Drug Interactions
Lithium
May increase lithium plasma concentrations and toxicity.
Warfarin
Increased risk of bleeding. Monitor INR.
Diuretics
Reduced diuretic and antihypertensive effects.
Rifampicin
May decrease Etoricoxib plasma concentrations.
Methotrexate
May increase methotrexate toxicity. Monitor for toxicity.
Oral Contraceptives
May increase ethinylestradiol exposure, increasing risk of adverse events.
ACE inhibitors/Angiotensin II antagonists
Reduced antihypertensive effect and increased risk of renal impairment.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, seek immediate medical attention. Symptomatic and supportive measures should be taken. There is no specific antidote for Etoricoxib overdose.
Pregnancy & Lactation
Not recommended during pregnancy, especially in the third trimester, due to potential risks to the fetus (e.g., premature closure of ductus arteriosus). Avoid during lactation as Etoricoxib is excreted in breast milk.
Side Effects
Contraindications
- Hypersensitivity to Etoricoxib or any component of the tablet
- Active peptic ulceration or gastrointestinal bleeding
- Severe hepatic dysfunction
- Severe renal dysfunction (creatinine clearance <30 mL/min)
- Congestive heart failure (NYHA Class II-IV)
- Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
- Uncontrolled hypertension
Drug Interactions
Lithium
May increase lithium plasma concentrations and toxicity.
Warfarin
Increased risk of bleeding. Monitor INR.
Diuretics
Reduced diuretic and antihypertensive effects.
Rifampicin
May decrease Etoricoxib plasma concentrations.
Methotrexate
May increase methotrexate toxicity. Monitor for toxicity.
Oral Contraceptives
May increase ethinylestradiol exposure, increasing risk of adverse events.
ACE inhibitors/Angiotensin II antagonists
Reduced antihypertensive effect and increased risk of renal impairment.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, seek immediate medical attention. Symptomatic and supportive measures should be taken. There is no specific antidote for Etoricoxib overdose.
Pregnancy & Lactation
Not recommended during pregnancy, especially in the third trimester, due to potential risks to the fetus (e.g., premature closure of ductus arteriosus). Avoid during lactation as Etoricoxib is excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date, depending on specific manufacturer and storage conditions.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by regulatory bodies (e.g., DGDA, EMA)
Patent Status
Generic available, patent expired for original compound
Clinical Trials
Etoricoxib has undergone extensive clinical trials demonstrating its efficacy and safety in various pain and inflammatory conditions. Studies have compared its cardiovascular and gastrointestinal safety profile with other NSAIDs.
Lab Monitoring
- Regular monitoring of blood pressure, especially at the start of treatment.
- Periodic monitoring of liver function tests (LFTs) and kidney function tests, especially in patients with pre-existing conditions or on long-term therapy.
- Monitoring for signs of gastrointestinal bleeding.
Doctor Notes
- Prescribe the lowest effective dose for the shortest possible duration to minimize cardiovascular and gastrointestinal risks.
- Carefully assess patients for cardiovascular risk factors before and during treatment.
- Avoid in patients with significant cardiovascular disease or uncontrolled hypertension.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not exceed the recommended dose or duration of treatment.
- Report any signs of stomach pain, black stools, or severe side effects to your doctor immediately.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Gleron 90 mg tablet may cause dizziness or somnolence (sleepiness) in some individuals. If you experience these effects, avoid driving or operating machinery.
Lifestyle Advice
- Avoid excessive alcohol consumption while taking this medicine, especially if you have a history of stomach problems.
- Monitor your blood pressure regularly.
- Discuss any concerns about cardiovascular risks with your doctor, especially if you have pre-existing heart conditions.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.